Posted On: 27 Jan 2026
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q2 FY2026 have been released.
Quarter over quarter, total prescriptions shipped for Sofdra® (sofpironium) increased 24% to 25,351, and net revenue increased 28% to $9.1 million.